Overview

ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The primary aim of this observational study is to collect safety and effectiveness data for bortezomib used at first relapse in a group of multiple myeloma patients who received specific and well defined first line treatments within previous clinical studies.
Details
Lead Sponsor:
Janssen-Cilag B.V.
Treatments:
Bortezomib